Skip to Main Content

Paper Details

Phase II study of the histone deacetylase inhibitor vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in recurrent or metastatic transitional cell carcinoma of the urothelium - an NCI-CTEP sponsored: California Cancer Consortium trial, NCI 6879.
Invest New Drugs
14
2021
Author NameAffiliation
David I QuinnUniversity of Southern California Norris Comprehensive Cancer Center
Primo N LaraUniversity of California Davis Cancer Center
  • 1 - 2

Datasets

Release 1.2